CEPI (Coalition for Epidemic Preparedness Innovations)
Helene Holth Skatvedt is an experienced legal professional currently serving as Associate General Counsel at CEPI, with a tenure starting in May 2023. Prior to this role, Helene held various significant positions at Novartis Norge from May 2016 to April 2023, including Head Legal Norway and Country Manager Oncology Norway. Helene also contributed as a legal advisor during a short-term rotation with Novartis China in 2019. Before joining Novartis, Helene worked at Klagenemnda for kvoteordningen for melk and Advokatfirmaet BA-HR DA, focusing on competition law. Helene's career includes a role as Senior Adviser at the Norwegian Ministry of Government Administration, Reform and Church Affairs, where work involved competition law and EEA state aid rules. Helene's educational background includes a law degree from the University of Oslo and studies at Université Francois-Rabelais in France and The New School.
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net